Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls

A. H. Boekhout*, A. Rogiers, K. Jozwiak, M. J. Boers-Sonderen, A. J. van den Eertwegh, G. A. Hospers, J. W. B. de Groot, M. J. B. Aarts, E. Kapiteijn, A. J. ten Tije, D. Piersma, G. Vreugdenhil, A. A. van der Veldt, K. P. M. Suijkerbuijk, E. A. Rozeman, B. Neyns, K. J. Janssen, L. V. van de Poll-franse, C. U. Blank

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Web of Science)
Original languageEnglish
Pages (from-to)69-77
Number of pages9
JournalActa Oncologica
Volume60
Issue number1
Early online date12 Sep 2020
DOIs
Publication statusPublished - 2 Jan 2021

Keywords

  • Melanoma
  • immune checkpoint inhibition
  • health-related quality of life
  • survivors
  • matched controls
  • RESECTED STAGE-III
  • HOSPITAL ANXIETY
  • CANCER
  • IPILIMUMAB
  • DEPRESSION
  • PEMBROLIZUMAB
  • NIVOLUMAB
  • OUTCOMES
  • FATIGUE
  • IMPACT

Cite this